Tahoe Therapeutics has secured $30 million in new funding to create a massive dataset for training Virtual Cell Models. The company aims to generate one billion single-cell datapoints, mapping one million drug-patient interactions, and supporting the discovery of precision medicines for cancer and beyond.
The funding round was led by Amplify Partners, with other investors including Databricks Ventures, Wing Venture Capital, and General Catalyst. This raise follows the release of Tahoe-100M, a world’s first gigascale perturbative single-cell dataset that has been downloaded nearly 100,000 times.
Tahoe plans to expand on this foundation by creating an even larger dataset, aiming to reduce clinical trial failure rates and accelerate the development of precision medicines. The company is also advancing its own therapeutic programs toward the clinic and launching a new model of strategic collaboration with pharmaceutical or AI companies.
The funding will support Tahoe’s mission to bring about the “GPT moment” for AI models of human cells, translating insights to clinical readouts, and developing new medicines with much lower clinical failure rates. With this investment, Tahoe is poised to revolutionize cancer treatment and other diseases by leveraging its cutting-edge technology platform.
Source: https://www.citybiz.co/article/729394/general-catalyst-joins-30m-round-for-tahoe-therapeutics